Multiple Sclerosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Multiple Sclerosis stocks.

Multiple Sclerosis Stocks Recent News

Date Stock Title
Apr 19 TEVA Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S.
Apr 19 TEVA Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Apr 18 SNY Sanofi to overhaul US operations of vaccines, cut jobs
Apr 18 TEVA 3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Apr 17 SNY IGM Biosciences announces refocusing of Sanofi collaboration
Apr 17 BCLI BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer
Apr 17 SNY Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Apr 16 BCLI BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Apr 16 TEVA FDA approves Alvotech biosimilar of J&J top-selling drug Stelara
Apr 16 TEVA Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Apr 16 GMAB Genmab Acquires A Missing Piece For Its Pipeline
Apr 16 CTNM UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
Apr 16 TEVA Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Apr 16 GMAB Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Apr 15 TEVA Israeli economy has proven to thrive despite crisis: Expert
Apr 15 GMAB Roche reports survival data for new dual-acting lymphoma drug
Apr 15 GMAB Transactions in Connection with Share Buy-back Program Genmab
Apr 13 TEVA AbbVie keeps Humira market share near 100% despite biosimilars: report
Apr 12 SNY Sanofi: Information concerning the total number of voting rights and shares - March 2024
Multiple Sclerosis

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often remain, especially as the disease advances.While the cause is not clear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors such as being triggered by a viral infection. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.There is no known cure for multiple sclerosis. Treatments attempt to improve function after an attack and prevent new attacks. Medications used to treat MS, while modestly effective, can have side effects and be poorly tolerated. Physical therapy can help with people's ability to function. Many people pursue alternative treatments, despite a lack of evidence of benefit. The long-term outcome is difficult to predict, with good outcomes more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks. Life expectancy is on average 5 to 10 years lower than that of an unaffected population.Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. In 2015, about 2.3 million people were affected globally with rates varying widely in different regions and among different populations. That year about 18,900 people died from MS, up from 12,000 in 1990. The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men. MS was first described in 1868 by Jean-Martin Charcot. The name multiple sclerosis refers to the numerous scars (sclerae—better known as plaques or lesions) that develop on the white matter of the brain and spinal cord. A number of new treatments and diagnostic methods are under development.

Browse All Tags